PTPA and neoplasm: We only proved the effect of PP2A inhibition in the “primary” resistance to ICB, reprograming cold into hot inflamed tumours and improving anti–PD-1 immunotherapy, but did not examine whether mRNA dysregulation or mutations of these genes also play a role in the adaptive and acquired resistance to ICB37, future studies will also need to address the unravelling complexity associated with these dynamic treatment responses54.